Elixinol (ASX:EXL) share price heats up on cannabis business update

The Elixinol share price is rising today after the company released its quarterly activity update, outlining "green shoots" in the company's COVID-19 recovery.

| More on:
ASX Cannabis share price represented by asx investor holding card with cannabis leaf on it

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Elixinol Global Ltd (ASX: EXL) share price is rising today after the company released its quarterly activity update.

At the time of writing, the Elixinol share price is up 5.88% to 18 cents per share.

Elixinol's focus is the manufacture and distribution of industrial hemp products and early-stage medical cannabis business focusing on the importation, cultivation, manufacture and distribution of CBD and THC products (using the active compounds in marijuana). 

Elixinol's quarterly business update

Elixinol's focus in its latest update was its "highly value-accretive" acquisition of leading German hemp-derived CBD player, CannaCare Health. According to the company the acquisition will deliver fast market entry and immediate, material scale in Europe's fastest growing CBD market.

Elixinol also highlighted its financial position, stating it was "well-funded", with $23.3 million in cash and equivalents to support acquisitive growth and sustain conditions in those markets — particularly its European ambitions — that are still COVID-affected.

In terms of sales, Elixinol reported a first-quarter FY2021 revenue of $2.3 million, which was a 26% decline on the previous quarter. In that period the company made $3.1 million.

In some good regulatory news for Elixinol, its products are now supported by a valid novel food application under the UK Food Standards Agency (FSA), which could lead to greater sales revenue in the future.

It's predicting growth in that market over the coming months, as the UK re-emerges from lockdown and Elixinol retailers begin to restock their orders.

What Elixinol management said

Elixinol Global CEO, Oliver Horn, said the company had struggled due to the coronavirus pandemic.

The first quarter of the calendar year is traditionally softer for retail, while consumers curb discretionary spend after Christmas and holiday trading periods. This seasonal trend was compounded by the continued impact of COVID in two of our key markets: the UK and US, where footfall into physical venues continued to be significantly reduced.

Pleasingly, in March we saw green shoots start to appear both in the UK and the US as the impact of economic stimulus packages, easing of COVID restrictions came into effect and increased vaccination rates started lifting consumer confidence.

Elixinol share price snapshot

The Elixinol share price has been a relatively steady faller since a very short-lived high of 47 cents a share in May 2020. Since then it's risen above 25 cents in December 2020 and February 2021, but has spent most of its time below the 20 cent mark.

It's now level with the start of 2021, but has lost 45% over the past 12 months. 

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »